MARKET

XNCR

XNCR

Xencor
NASDAQ

Real-time Quotes | Nasdaq Last Sale

48.50
+0.39
+0.81%
After Hours: 48.50 0 0.00% 16:03 01/22 EST
OPEN
47.74
PREV CLOSE
48.11
HIGH
48.79
LOW
46.06
VOLUME
201.69K
TURNOVER
--
52 WEEK HIGH
50.57
52 WEEK LOW
19.35
MARKET CAP
2.79B
P/E (TTM)
-33.4806
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Daily Biotech Pulse: Fluidigm's Saliva-Based COVID Test Approved In Europe, China Backs Amarin's Vascepa
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 21)
Benzinga · 1d ago
The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 20)
Benzinga · 2d ago
miRagen Therapeutics Announces Company Name Change to Viridian Therapeutics and New Executive Appointments, Including Expansion of Leadership Team
Jonathan Violin, Ph.D., M.B.A. appointed President, CEO and director Barrett Katz, M.D., M.B.A. joins Viridian as Chief Medical Officer Viridian is...
GlobeNewswire · 4d ago
MorphoSys and Incyte Announce Acceptance by Health Canada of the New Drug Submission for Tafasitamab
MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) and Incyte (NASDAQ:INCY) today announced that Health Canada has accepted the New Drug Submission (NDS) for tafasitamab, an anti-CD19 antibody. The application seeks approval of tafas...
ACCESSWIRE · 01/12 21:30
The Daily Biotech Pulse: GSK, Vir To Start COVID-19 Antibody Study, Novartis In-Licenses BeiGene's Cancer Drug, Earnings Preannouncements Continue
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 11)
Benzinga · 01/12 13:15
Xencor Reports In 13G Filing A 7.6% Stake In Miragen Therapeutics
-SEC Filing
SEC Filing · 01/11 17:13
Global Bi-Specific Antibodies Therapy Market 2020 Report Presents Complete Summary, Marketplace Shares and Growth Opportunities by 2025
Jan 10, 2021 (CDN Newswire via Comtex) -- MarketsandResearch.biz has announced a new market research study namely Global Bi-Specific Antibodies Therapy...
CDN Newswire · 01/10 15:12
The Daily Biotech Pulse: Sarepta Gene Therapy Study Readout, Novavax Vaccine Supply Deal, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 7)
Benzinga · 01/08 12:25
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of XNCR. Analyze the recent business situations of Xencor through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 12 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average XNCR stock price target is 51.00 with a high estimate of 60.00 and a low estimate of 31.00.
EPS
Institutional Holdings
Institutions: 224
Institutional Holdings: 63.63M
% Owned: 110.75%
Shares Outstanding: 57.46M
TypeInstitutionsShares
Increased
61
2.18M
New
39
-281.95K
Decreased
48
1.34M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.07%
Pharmaceuticals & Medical Research
+0.80%
Key Executives
President/Chief Executive Officer/Founder/Director
Bassil Dahiyat
Chief Financial Officer/Vice President
John Kuch
Senior Vice President/Chief Scientific Officer
John Desjarlais
Senior Vice President
Allen Yang
Vice President/General Counsel/Secretary
Celia Eckert
Lead Director/Independent Director
A. Montgomery
Vice President
Jeremy Grunstein
Vice President
Eric Kowack
Vice President
Kirk Rosemark
Other
Julie Casciani
Lead Director/Independent Director
A. Bruce Montgomery
Independent Director
Ellen Feigal
Independent Director
Kevin Gorman
Independent Director
Kurt Gustafson
Independent Director
Yujiro Hata
Independent Director
Richard Ranieri
Independent Director
Dagmar Rosa-Bjorkeson
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About XNCR
Xencor, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases. It is also developing a pipeline of bispecific antibody candidates using its heterodimer Fc bispecific technology: XmAb14045, which is in a Phase I trial for the treatment of acute myeloid leukemia (AML); XmAb13676, which is in a Phase I trial for the treatment of B-cell malignancies; XmAb18087, which is in preclinical development for the treatment of neuroendocrine tumors, and XmAb20717, which is in preclinical development for the treatment of various cancers and is its dual checkpoint inhibitor.
More

Webull offers kinds of Xencor Inc stock information, including NASDAQ:XNCR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XNCR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading XNCR stock methods without spending real money on the virtual paper trading platform.